On May 13, 2021 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, to be held virtually June 4 – 8, 2021 and the European Hematology Association (EHA) (Free EHA Whitepaper) annual congress, to be held virtually June 9 – 17, 2021 (Press release, TG Therapeutics, MAY 13, 2021, View Source [SID1234580027]). Details of the data presentations are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, "We are excited to share updated data for TG-1701, our novel BTK inhibitor, as a monotherapy, and as a triple therapy with U2, at the upcoming ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) annual congresses. The EHA (Free EHA Whitepaper) abstract released yesterday included an update from the data most recently presented at the ASH (Free ASH Whitepaper) 2020 congress, and we are pleased to see with additional patients and longer follow-up the data continue to show TG-1701 to be efficacious and generally well tolerated in combination with U2. We look forward to updating the abstract data and presenting at both the upcoming ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) annual congresses."

Data to be presented at the ASCO (Free ASCO Whitepaper) meeting:

Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Abstract ID: 7525
Available on Demand: Friday, June 4, 2021 at 9:00 AM ET
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
The above abstract will be available on May 19, 2021, via the ASCO (Free ASCO Whitepaper) meeting website at www.asco.org.

Data to be presented at the EHA (Free EHA Whitepaper) meeting:

Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ubituximab and Umbralisib (U2) in Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Abstract Code: EP638
Available on Demand: Friday, June 11, 2021 at 9:00 CEST
Session Title: Chronic lymphocytic leukemia and related disorders – Clinical
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
The above abstract is now available via the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org.

At the time of each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm